Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy

Tumori

Volumn 89, Issue 2, 2003, Pages 111-116

  Della Torre, Silvia ^a   Procopio, Giuseppe ^a   Fusi, Alberto ^a   Catena, Laura ^a   Ferrari, Leonardo ^a   Nova, Paola ^a   Denaro, Angela ^a   Bichisao, Ettore ^b   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Ital Trials in Clin Oncol (ITMO)   (Italy)

Author keywords

Biotherapy; Chemotherapy; Interferon; Neuroendocrine tumors; Somatostatin analogues

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHLOROZOTOCIN; CISPLATIN; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; LOMUSTINE; MITOXANTRONE; OCTREOTIDE; PACLITAXEL; PENTETREOTIDE; PLATINUM DERIVATIVE; RECOMBINANT ALPHA INTERFERON; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CARCINOID SYNDROME; CHRONIC FATIGUE SYNDROME; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; EARLY DIAGNOSIS; FATIGUE; FEVER; FLU LIKE SYNDROME; HEART DISEASE; HUMAN; LEUKOPENIA; LIVER DISEASE; MONOTHERAPY; MYALGIA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NEUROPATHY; REVIEW; SYMPTOM; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

EID: 0038545846     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900201     Document Type: Review

References (43)

1. Pearse AGE: The diffuse neuroendocrine system and the APUD concept: related 'endocrine' peptides in brain, intestine, pituitary, placenta and human cutaneous glands. Med Biol, 55: 115-125, 1977.
2. Fontaine J, Le Douarin NM: Analysis of endoderm formation in the avian blastoderm by use of qual-chick chimeras. Fed Proc, 38: 2289-2294, 1979.
3. Modlin IM, Sandor A: An analysis of 8305 cases of carcinoid tumours. Cancer, 79: 813-829, 1997.
4. Oberndorfer S: Karzinoide tumouren des dunndarms. Frankf Zschr Pathol, 1: 426-430, 1907.
5. Pearse AGE: Genesis of neuroenocrine system. In: Surgical endocrinology. Frisen SR, Thompson NW (Eds), Lippincott, Philadelphia, pp 25-35, 1990.
6. Solcia E, Kloppel G, Sobin LH: Histologic typing of endocrine tumours. WHO International Histological Classification of Tumours, Springer Verlag, Heidelberg, 2000.
7. Moertel CG, Kvols LK, O'Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variance of these neoplasms. Cancer, 68: 227-232, 1991.
8. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, Regalia E, Cassata A, Procopio G, Mariani L: 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer, 83: 372-378, 1998.
9. Oberg K: Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol, 12 (Suppl 2): 111-114, 2001.
10. Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, Grossman AB, Besser GM: Treatment of advanced neuroendocrine tumours using a combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol, 57: 169-183, 2002.
11. Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L, Dogliotti L, Pinotti G, Aitini E, Labianca R, Fornasiero A, Riva P, Schieppati G, Nelli P, Mariani L: Treatment of metastatic carcinoid and other neuroendocrine tumours with recombinant interferon alpha-2a. Cancer, 72: 3099-3100, 1993.
12. Funa K, Alm GV, Ronnblom L, Oberg K: Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leukocyte interferon. Clin Exp Immunol, 53: 716-724, 1983.
13. Oberg K: Interferon in the management of neuroendocrine GEP tumours. Dig, 62 (Suppl 1): 92-97, 2000.
14. Bajetta E, Procopio G, Buzzoni R, Catena L, Ferrari L, Del Vecchio M: Advanced in diagnosis and therapy of neuroendocrine tumours. Expert Rev Anticancer Ther, 1: 89-99, 2001.
15. Moertel CG, Rubin J, Kvols LK: Therapy of metastatic carcinoid tumour and the management carcinoid with recombinant leukocyte A interferon. J Clin Oncol, 7: 865-868, 1989.
16. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R: Combination therapy with octreotide and alpha-interferon: effect on tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gastroenterology, 94: 155-159, 1999.
17. Fjallskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksonn B: Treatment of malignant endocrine pancreatic tumours with combination of alpha-interferon and somatostatin analogs. Med Oncol, 19: 35-42, 2002.
18. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K: Induction of apoptosis in neuroendocrine tumours of the digestive system during treatment with somatostatin analogues. Acta Oncol, 36: 607-614, 1997.
19. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P: Treatment of carcinoid syndrome. A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability and tolerance. Cancer, 88: 770-776, 2000.
20. Oberg K, Norheim I, Theodorsson E: Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol, 30: 503-507, 1991.
21. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, Di Leo A: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumours. A study by the Italian Trials in Medical Oncology Group (ITMO). Cancer, 77: 402-408, 1996.
22. Harris AG, Redfern JS: Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data. Aliment Pharmacol Ther, 9: 387-394, 1995.
23. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, Kelsen D: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumours. Cancer, 72: 244-248, 1993.
24. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C, Dennler HJ: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut, 38: 430-438, 1996.
25. Wymenga AN, Eriksson B, Salmela PT, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG, Oberg KE: Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumours and hormone-release symptoms. J Clin Oncol, 17: 1111-1117, 1999.
26. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Bernades P, Rougier P: Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut, 39: 279-283, 1996.
27. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Can, 37: 1014-1019, 2001.
28. Arnold R, Simon B, Wied M: Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion, 62: 84-91, 2000.
29. Rubin J, Ajani J, Schrimer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L: Octreotide acetate long-acting formulation versus open-label sc octreotide acetate in malignant carcinoid syndrome. J Clin Oncol, 88: 600-606, 1999.
30. Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF: Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumours pretreated with lanreotide. Ann Oncol, 11: 1127-1130, 2000.
31. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O: Long-term survival of atypical bronchial carcinoids with liver metastases treated with octreotide. Eur J Cardiothorac Surg, 21: 913-917, 2002.
32. Eriksson B, Renstrup J, Imam H, Oberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumour: clinical and biologic effect. Ann Oncol, 8: 1041-1044, 1997.
33. Rivera E, Ajani JA: Doxorubicin, streptozotocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin, 21: 38-48, 1998.
34. Schlumberger M, Abdelmoumene N, Delisle, Covette JE: Treatment of advanced medullary thyroid cancer with an alternating combination of 5-FU-streptozotocin and 5-fudacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GECT). Br J Cancer, 71: 363-365, 1995.
35. Ridolfi R, Amaducci L, Derni S, Fabbri L, Innocenti MP, Vignutelli P: Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumours of gastrointestinal origin: experiences with 13 patients. J Chemother, 3: 328-331, 1991.
36. Di Bartolomeo M, Bajetta E, Bochicchio AM: A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with NETs. A study by ITMO group. Ann Oncol, 6: 77-79, 1995.
37. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E: Efficacy of chemotherapy combinations for the treatment of metastatic neuroendocrine tumours. Ann Oncol, 13: 614-621, 2002.
38. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer, 81: 1351-1355, 2000.
39. Fjallskog ML, Granberg D, Welin S, Eriksson C, Oberg KE, Janson ET, Eriksson BK: Treatment with cisplatin and etoposide in patients with neuroendocrine tumours. Cancer, 92: 1101-1107, 2001.
40. Bukowski RM, Tangen CM, Peterson RF, Taylor SA, Rinettart JJ: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastastic carcinoid. Cancer, 73: 1505-1508, 1994.
41. Neijt JP, Lacave AJ, Splinter TAW, Taal BG, Veenhof CH, Sattmond T, Lips CJ: Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-intestinal Cancer Cooperative Group. Br J Cancer, 71: 106-108, 1995.
42. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mattoney MR, Rubin J: A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumours. Cancer, 91: 1543-1548, 2001.
43. Saltz L, Lauwers G, Wiseberg J, Kelsen D: A phase II trial of carboplatin in patients with advanced APUD tumours. Cancer, 72: 619-622, 1993.